Author:
Zhou Du-Chao,Lu Yu-Ting,Mai Yan-Wen,Zhang Chen,Xia Jie,Yao Pei-Fen,Wang Hong-Gen,Huang Shi-Liang,Huang Zhi-Shu
Funder
Guangdong Provincial Key Laboratory of Construction Foundation
Subject
Organic Chemistry,Drug Discovery,Molecular Biology,Biochemistry
Reference22 articles.
1. DNA topoisomerases: structure, function, and mechanism;Champoux;Annu. Rev. Biochem.,2001
2. Catalytic topoisomerase II inhibitors in cancer therapy;Larsen;Pharmacol. Ther.,2003
3. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II;Jensen;Cancer Res.,1991
4. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test;Lehmann;Environ. Mol. Mutagen.,2004
5. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses;Morgan;Mol. Pharmacol.,2000
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献